Thymosin β 4 preserves vascular smooth muscle phenotype in atherosclerosis via regulation of Low Density Lipoprotein Related Protein 1 (LRP1).

Sonali Munshaw¹, Andia Redpath¹, Benjamin Pike¹ & Nicola Smart^{1*}.

1. Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy & Genetics, University of Oxford, Sherrington Building, South Parks Road, Oxford OX1 3PT, UK.

Short title: Thymosin β 4 protects in atherosclerosis via LRP1

*Correspondence to:

Dr Nicola Smart

Department of Physiology, Anatomy & Genetics

University of Oxford

Sherrington Building

South Parks Road

Oxford

OX1 3PT

Tel: +44 (0)1865 282365

nicola.smart@dpag.ox.ac.uk

Abstract

Objective:

Atherosclerosis is a progressive, degenerative vascular disease and a leading cause of morbidity and mortality. In response to endothelial damage, platelet derived growth factor (PDGF)-BB induced phenotypic modulation of medial smooth muscle cells (VSMCs) promotes atherosclerotic lesion formation and destabilisation of the vessel wall. VSMC sensitivity to PDGF-BB is determined by endocytosis of Low density lipoprotein receptor related protein 1 (LRP1)-PDGFR β complexes to balance receptor recycling with lysosomal degradation. Consequently, LRP1 is implicated in various arterial diseases. Having identified T β 4 as a regulator of LRP1-mediated endocytosis to protect against aortic aneurysm, we sought to determine whether T β 4 may additionally function to protect against atherosclerosis, by regulating LRP1-mediated growth factor signalling.

Approach and Results:

By single cell transcriptomic analysis, *Tmsb4x*, encoding T β 4, strongly correlated with contractile gene expression and was significantly down-regulated in cells that adopted a modulated phenotype in atherosclerosis. We assessed susceptibility to atherosclerosis of global T β 4 knockout mice using the ApoE^{-/-} hypercholesterolaemia model. Inflammation, elastin integrity, VSMC phenotype and signalling were analysed in the aortic root and descending aorta. T β 4KO; ApoE^{-/-} mice develop larger atherosclerotic plaques than control mice, with medial layer degeneration characterised by accelerated VSMC phenotypic modulation. Defects in T β 4KO; ApoE^{-/-} mice phenocopied those in VSMC-specific LRP1 nulls and, moreover, were underpinned by hyperactivated LRP1-PDGFR β signalling.

Conclusions:

We identify an atheroprotective role for endogenous T β 4 in maintaining differentiated VSMC phenotype via LRP1-mediated PDGFR β signalling.

Introduction

Atherosclerosis is a dynamic arterial disease, initiated by endothelial dysfunction¹. Subendothelial lipid retention provokes a maladaptive inflammatory response and leads to the formation of atheromatous plaques, characterised by a necrotic core and enveloped by a fibrous cap². The resultant loss of vessel wall integrity is detrimental, predisposing affected individuals to an array of complications, including aneurysm and thrombosis. Whilst gradual occlusion of vessels may precipitate as claudication, the principal clinical consequences arise from thrombotic and embolic events associated with unstable plaques that are prone to erosion or rupture³. The consequent cardiovascular morbidities – which include coronary heart disease, ischaemic stroke and peripheral artery disease – remain a major societal burden, for which interventions beyond lifestyle change are relatively limited⁴.

Plaque stability is determined by opposing degenerative and regenerative processes. Degradation of the medial layer is mediated by the proteolytic actions of macrophages and potentiated by pro-inflammatory signalling, while the reparative response comprises vascular wall remodelling and synthesis of extracellular matrix (ECM), processes ascribed to vascular smooth muscle cells (VSMCs)⁵. In healthy tissue, VSMCs are chiefly localised to the tunica media, maintaining a fully differentiated contractile phenotype to regulate vascular tone. This state is defined by expression of proteins of the contractile apparatus, including smooth muscle myosin heavy chain (*Myh11*), alpha-smooth muscle actin (*Acta2*) and transgelin (*Tagln*)⁶. However, in atherosclerosis, environmental triggers initiate a growth factor-mediated phenotypic transition causing VSMCs to de-differentiate, down-regulate contractile marker expression, proliferate, and migrate to the intimal layer⁷. Modulated, so-called ‘synthetic’ VSMCs, are proposed to adopt a phenotype that is either macrophage-like, pro-inflammatory, and destabilising, or fibroblast-like, synthetic, and stabilising⁸. Although reparative in the short term, chronic VSMC dedifferentiation exacerbates inflammation to promote atherosclerotic lesion development, leading to arterial stiffness and stenosis⁹. Therefore, in the main, inhibiting VSMC phenotypic transformation has been shown to attenuate progression of vascular disease¹⁰.

Various signalling pathways, including transforming growth factor (TGF)β, NOTCH, Wnt and Sonic hedgehog (Shh), promote mural cell differentiation during development and serve to maintain VSMC contractile state in the adult vasculature (summarised in ¹¹). Conversely, the contractile-synthetic phenotypic modulation of VSMCs is induced primarily by platelet-derived growth factor (PDGF)-BB, levels of which increase markedly in response to endothelial damage¹². The response of VSMCs to PDGF-BB is determined by the extent of PDGF

receptor β (PDGFR β) exposure at the cell surface, which is controlled by endocytic trafficking in complex with the co-receptor, Low density lipoprotein (LDL) receptor related protein 1 (LRP1)¹³. Following internalisation and transduction of signals to nuclear effectors, LRP1-PDGFR β complexes may be recycled to the cell membrane or targeted for lysosomal degradation, to potentiate or attenuate downstream signalling activity, respectively¹⁴. We recently defined a key role for the small peptide Thymosin β 4 (T β 4) in regulating LRP1-PDGFR β trafficking to control VSMC phenotype and protect against abdominal aortic aneurysm (AAA)¹⁵. This study demonstrated a postnatal VSMC-autonomous role for T β 4 to maintain VSMC differentiation for vascular homeostasis beyond its developmental role to induce aortic VSMC differentiation¹⁶. Because of its central role in controlling the sensitivity of VSMCs to growth factors, LRP1 has been implicated through genome-wide association and animal studies in protection against a range of arterial diseases, including AAA¹⁷, carotid¹⁸ and coronary artery disease¹⁹. We therefore sought to determine whether T β 4 functions to protect against atherosclerosis by regulating LRP1-PDGFR β signalling to preserve VSMC phenotype. In a murine model of atherosclerosis, T β 4-null mice displayed an exacerbated phenotype, relative to controls, forming large plaques in the aortic sinus and descending aorta. Notably, accelerated disease progression closely phenocopies that observed in VSMC-specific *Lrp1* knockout mice. While inflammation in the aorta was unaltered in T β 4 mutants, augmented plaque formation was characterised by accelerated VSMC phenotypic modulation and elastolysis, underpinned by dysregulated LRP1-PDGFR β signalling. These findings support a common mechanism through which the T β 4-LRP1 axis controls growth factor signalling, VSMC differentiation and protection against aortic diseases.

Methods

Mouse lines. Mice were housed and maintained in a controlled environment and all procedures involving the use and care of animals were performed in accordance with the Animals (Scientific Procedures) Act 1986 (Home Office, United Kingdom) and approved by the University of Oxford Animal Welfare and Ethical Review Boards. All mice used for the study were maintained on the C57Bl6/J background for at least 20 generations. The global T β 4 Knockout strain, in which exon 2 of *Tmsb4x* locus is deleted, were a kind gift of Martin Turner, Babraham Institute and have been previously described¹⁶. VSMC-specific *Lrp1* knockouts were generated by crossing the previously described floxed *Lrp1* line²⁰ (obtained from Jax) to homozygosity with *Myh11*^{CreERT2}, to generate *Myh11*^{CreERT2}; *Lrp1*^{fl/fl}. These lines were crossed to homozygosity with *ApoE*^{-/-} mice²² (from Jax). Conditional knockout of *Lrp1* was induced by oral gavage of 3 week old mice with 3 doses of tamoxifen (80mg/kg) on alternate days.

Atherosclerosis model. Age-matched (8-12 week old) mice, on the ApoE^{-/-} background, were fed on Western diet (21.4% fat; 0.2% cholesterol; Special Diets Services, Essex, UK) for up to 12 weeks. Mice were weighed weekly and, at harvest, serum collected for cholesterol analysis (by Charles River Laboratories). EdU(5-ethynyl-2'-deoxyuridine), prepared in 0.9% saline, was administered at a dose of 150mg/kg by intraperitoneal injection (4 doses over the 2 weeks prior to harvest).

Single cell RNA sequencing analysis. 10X Chromium data were downloaded as cell-gene count matrices from GSE131776²³. The scRNA-seq dataset, specifically the tdTomato positive VSMC lineage, was analysed using Seurat^{24, 25} in R, as follows. Cells with more than 8% mitochondrial reads, more than 3500 or fewer than 1000 genes per cell were filtered out. The principal component analysis was used to cluster cells, which were visualized with the UMAP method²⁶ and biological samples – Baseline, 8 and 16 week HFD – were integrated using Harmony²⁷. Differential expression (DE) analysis Wilcoxon rank-sum test was carried out between biological samples and clusters, to identify upregulated and downregulated genes (Log2FC) with significant adjusted p- value (Bonferroni correction).

Histological Sample Preparation. For histological and immunohistochemical analyses, mouse aortic sinus, aortic arch and descending aorta were harvested, washed in phosphate-buffered saline (PBS; pH7.4) and fixed in 4% paraformaldehyde (PFA) at room temperature, either for two hours (cryosectioning) or overnight (paraffin embedding). For histological analysis, samples were dehydrated using a series of graded ethanol concentrations (50-100%, each for at least 2 hours), and cleared in butanol overnight. Samples were incubated at 60°C in 1:1 butanol: molten pastillated fibrowax for 30 minutes, then three times in 100% molten wax, each for 4 hours to overnight, before embedding and sectioning (10µm transverse sections). Paraffin sections were stained with Oil red O solution, Hematoxylin and Eosin, Elastic stain kit (Verhoeff van Gieson) and Masson's Trichrome kit (all from *Sigma-Aldrich*), each according to the manufacturer's protocol. After imaging, morphology was assessed on sections which had been anonymised and blinded for genotype. Elastin breaks per section were counted manually. Plaque area and aortic diameter were measured using ImageJ. Elastin breaks/score, aortic diameter, TA/AA plaque size are all expressed as the mean of 6 sections per aorta) For immunohistochemical analyses, fixed tissues were rinsed in PBS and equilibrated in 30% sucrose (in PBS) overnight at 4°C. Samples were placed in 50:50 (30% sucrose: Tissue-Tek OCT), then embedded in OCT and chilled at -80°C.

Immunofluorescence Staining on Cryosections. Frozen sections of descending aorta or aortic sinus (base of the heart) were cut at a thickness of 10 µm, air-dried for 5 minutes and

rinsed in PBS. Sections were permeabilized in 0.5% Triton-X100/PBS for 10 minutes, rinsed in PBS and blocked for 1-2 hours (1% BSA, 10% goat serum or donkey serum; 0.1% Triton-X100 in PBS). Sections were incubated with primary antibodies (diluted as below) at 4°C overnight. Sections were washed 5-6 times in 0.1% Triton-X100 in PBS (PBST) then incubated in secondary antibody for 1 hour at room temperature. Sections were washed 3 times in PBST and, incubated with 300nmol/uL 4',6-diamidino-2-phenylindole (DAPI) in PBS for 5 minutes and rinsed a further twice in PBS. Slides were mounted with 50% glycerol:PBS and imaging was conducted on an Olympus FV1000 confocal microscope or a Leica DM6000 fluorescence microscope. Apoptosis was assessed using the Click-iT TUNEL Alexa Fluor 546 Imaging Assay kit and EdU incorporation by Click-iT EdU Alexa Fluor 546 Imaging Assay kit (both from ThermoFisher), according to the manufacturers' instructions. Antibodies used for Immunofluorescence: FITC-conjugated Mouse anti- α SMA (1:200; Sigma; F3777); Rabbit anti-Vimentin (1:200; Abcam; ab45939); Rat anti-CD68 (1:100; BioRad; MCA1957); Rabbit anti-Caldesmon (1:250 Abcam; ab32330); Rabbit anti-Thymosin β 4 (1:100; Immunodiagnostik; A9520); Rabbit anti-phospho-LRP1 (Tyr4507) (1:100; Santa Cruz Biotechnology, sc-33049); Rabbit anti-phospho-PDGFR β (Tyr1021) (1:100; Abcam, ab134048); Rabbit anti-HTRA1 (1:100; Abcam, ab38611); Rabbit anti-Lumican (1:200; Abcam, ab168348); AlexaFluor-conjugated secondary antibodies raised against Rat or Rabbit IgG (Invitrogen) were used at 1:200.

Immunoblotting. Aortic biopsies were lysed in ice cold RIPA buffer (Sigma) supplemented with 1mM dithiothreitol, phosphatase and protease inhibitor cocktail (PhosSTOP and cOmplete protease inhibitor cocktail; Roche). Western blots were performed using a standard protocol. Proteins were transferred by semi-dry transfer onto PVDF membrane. After blocking, membranes were probed with primary antibodies overnight. Antibodies used were Rabbit anti-phospho-Akt (S473) (1:500; Cell Signalling Technology, 4058), Rabbit anti-phospho-ERK1/2 (Thr202/Tyr204) (1:1000; Cell Signalling Technology, 9101), Rabbit anti-eIF4E (1:1000; Cell Signalling Technology, 2067), Rabbit anti- β -actin (1:1000; Abcam, ab8227). HRP-conjugated secondary antibodies were from GE Healthcare (rabbit, NA934) and R&D (sheep, HAF016).

RNA isolation and gene expression profile by quantitative real time (qRT-PCR). Total RNA was isolated from the aortic arch or descending aorta of adult mice using the RNeasy Fibrous Tissue Mini kit (Qiagen), according to the manufacturer's instructions. cDNA was prepared using RT kit (Applied Biosystems). qRT-PCR was performed on a ViiA 7 (Life technologies) using fast SYBR Green (Applied Biosystems). Data were normalised to β -actin expression (endogenous control, after selection of optimal control, in terms of stable

expression, from a panel of 6 genes). Fold-changes were determined by the $2^{-\Delta\Delta CT}$ method²⁸.

Primer sequences (5'-3'): *β-actin* F: GGCTGTATTCCCCTCCATCG; R: CCAGTTGGTAACAATGCCATGT; *sm22α* F: CAACAAGGGTCCATCCTACGG; R: ATCTGGGCGGGCCTACATCA; *Myh11* F: AAGCTGCGGCTAGAGGTCA; R: CCCTCCCTTTGATGGCTGAG; *Caldesmon* F: GCTCCCAAGCCTTCTGACTT; R: CCTTAGTGGGGGAAGTGACC; *Vimentin* F: TCCAGCAGCTTCCTGTAGGT; R: CCCTCACCTGTGAAGTGGAT; *Il1b* F: CAACCAACAAGTGATATTCTCCATG; R: GATCCACACTCTCCAGCTGCA; *tnfα* F: CACGTCGTAGCAAACCACCAAGTGGA; R: TGGGAGTAGACAAGGTACAACCC

Statistics. Randomisation of animals to treatment or genotype groups was introduced at the time of introduction of modified diet. Thereafter, tissues were processed and analysed by an independent observer, whilst blinded to treatment or genotype. Statistical analyses were performed with GraphPad Prism Software. For the quantitative comparison of two groups, two-tailed unpaired Student's t-test was used to determine any significant differences, after assessing the requirements for a t-test using a Shapiro-Wilk test for normality and an F-Test to compare variances. Alternatively, a Mann-Whitney non-parametric test was used. For comparison of three groups or more, a one-way ANOVA with Tukey's post-hoc test was used. For analyses involving two independent variables, a two-way ANOVA with Bonferroni, Holm-Sidak or Dunnett's post-hoc test was used. Significance is indicated in the figures, as follows: *: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$; ****: $p \leq 0.0001$.

Results

Phenotypic modulation of VSMCs in atherosclerosis is associated with down-regulation of *Tmsb4x*

To understand how endogenous Tβ4 levels are altered during disease, and whether they may influence contractile phenotype at the level of individual VSMCs, we first re-analysed published single-cell RNA sequencing (scRNA-Seq) data. The study by Wirka and colleagues utilised VSMC (*Tg^{Myh11-CreERT2}*) lineage traced mice on the ApoE^{-/-} background, to perform transcriptomic analyses at baseline and following 8 or 16 weeks of high-fat diet (HFD) to induce atherosclerosis²³. While the authors sequenced the full spectrum of cells in the aortic root and ascending aorta using the 10x Chromium platform, we focussed our analysis on the tdTomato-labelled cells determined to be of VSMC origin (Fig. 1A-C; Online Figure I). Across all time points, three discrete populations of contractile VSMCs could be discerned (ContSMC_1-3), based on differential gene expression, as well as a transcriptomically distinct

cluster of modulated VSMCs (ModSMC) and the pericyte population identified in the original study (heat map shown in Online Figure 1A). The contractile VSMC clusters exhibited enriched expression of canonical contractile markers, including *Myl9*, *Acta2*, *Tmp2*, and *Tagln*, and relatively low expression of so-called ‘synthetic’ markers – such as *Dcn*, *Lum*, and *Col1a1*. While contractile marker expression was comparatively uniform across all three contractile clusters, ContSMC_2 and ContSMC_3 were distinguished by higher expression of injury-response genes, including *Atf3*, *Sost*, and *Junb*, compared with ContSMC_1. Further separation of ContSMC_2 and ContSMC_3 related primarily to a higher expression of cell cycle arrest genes, such as *Gadd45b*, in ContSMC_3. The ModSMC cluster was characterised by a relative abundance of the ‘synthetic’ markers, including *Dcn*, *Lum*, and *Fln* – alongside a relative reduction of contractile markers, such as *Acta2*, *Myh11*, and *Cnn1* (Table I). The majority of enriched genes related to cell migration and extracellular matrix (ECM) functions, and also included markers associated with mesenchymal cell (*Sca1*) and macrophage (*Lgals3*) identity, consistent with previous descriptions of the modulated VSMC phenotype^{3, 29,}

30.

The contractile-synthetic VSMC phenotypic transition associated with plaque development was evidenced by a shift in cell composition after HFD feeding (Figure 1A and Online Figure 1B). From a baseline of 83% ContSMCs and 14.2% ModSMCs, the modulated population expanded, to account for 20.3% and 47.5% of VSMC lineage derivatives at 8 and 16 weeks, respectively, with a corresponding decrease of the contractile fraction to 73.6% and 49.9%, respectively. Even at baseline, levels of *Tmsb4x*, the transcript encoding Tβ4, were marginally lower in the ModSMC cluster, compared with ContSMCs (Figure 1B and Online Figure 1C). With HFD, a striking, progressive reduction in *Tmsb4x* expression was observed in this cluster, to the extent that *Tmsb4x* featured among the top 20 down-regulated genes, alongside canonical contractile markers, such as *Tnnt2*, *Acta2*, *Myl9*, *Myh11* and *Myl6* (log2FC<1, baseline vs 16 weeks’ HFD; Table II). With disease progression, *Tmsb4x* expression across the expanding ModSMC cluster became strongly correlated with contractile marker expression, as shown for *Tagln* (Pearson correlation coefficient = 0.79 at 8 weeks; 0.71 at 16 weeks; Figure 1C), with a negative correlation emerging between *Tmsb4x* and synthetic markers, exemplified by *Spp1*, only after HFD feeding (Pearson correlation coefficient = -0.54 at 8 weeks; -0.61 at 16 weeks Figure 1C). This relationship was validated at the protein level in aortic sinus sections from ApoE^{-/-} male mice after a period of HFD. Both Tβ4 and contractile protein α-smooth muscle actin (α-SMA) were abundantly expressed at baseline and early disease stages (3 weeks’ HFD, Figure 1D) and both declined with disease progression (7 weeks’ HFD, Figure 1D). Tβ4 expression strongly correlated with levels of α-SMA in medial

layer VSMCs (Pearson correlation coefficient = 0.69 (range 0.64-0.75 across both time points), quantified using Coloc2 in Image J; Figure 1D). Consistent with the scRNA-Seq, ModSMCs increased in number with disease progression and were more prominent within the lesion and were largely found within the fibrous caps. *Lum*, encoding the ECM protein Lumican, emerged from the scRNA-seq as a useful marker of modulated VSMCs (Online Figure IA, C, Table I). At baseline and early disease stages, Lumican expression was largely confined to the external elastic membrane and barely detectable in VSMCs (Figure 1D). However, with disease progression, a progressive up-regulation of Lumican was observed in an increasing number of VSMCs in the medial layer and fibrous cap (Figure 1D). Lumican-expressing modulated VSMCs had substantially lower levels of T β 4 and α SMA (Figure 1D; shown at 7 weeks' HFD;). Indeed, a striking inverse relationship between *Tmsb4x* and *Lum* is apparent within the ModSMC cluster across the disease time course (Online Figure IC). These data strongly support a correlative relationship between high T β 4 levels and maintenance of the contractile VSMC phenotype, consistent with its roles in promoting mural cell differentiation during development^{16, 31, 32}, in vascular homeostasis postnatally and in contractile VSMC preservation in a murine AAA model¹⁵.

Loss of T β 4 predisposes to atherosclerosis

To determine whether a reduction in T β 4 levels, as occurs during atherosclerosis, may contribute towards the modulation of VSMC state, we investigated the phenotype of T β 4-null male mice (T β 4^{-/-}) in a model of hypercholesterolaemia, by crossing onto the ApoE^{-/-} background²² and feeding a HFD (21.4% fat; 0.2% cholesterol) for up to 12 weeks. To evaluate the hypothesised common function for T β 4 and LRP1 in regulating VSMC phenotypic modulation, we generated a VSMC-specific *Lrp1* knockout (KO) line (Myh11^{Cre}; *Lrp1*^{fl/fl}; ApoE^{-/-}; tamoxifen-induced at 3 weeks of age), for comparison with T β 4 KO mice. Smooth muscle-specific *Lrp1* deletion, whether constitutively or inducibly targeted, strongly predisposes mice to develop atherosclerotic and aneurysmal disease^{13, 20, 33}. Advanced atherosclerotic lesions, containing large necrotic cores, were detected in the aortic sinus (Figure 2A, C) and descending thoracic aorta (Figure 2B, D) of all mice. By area, plaques were significantly larger in T β 4^{-/-}; ApoE^{-/-} mice than in T β 4^{+/-}; ApoE^{-/-} littermate controls and were comparable in size to those of Myh11^{Cre}; *Lrp1*^{fl/fl}; ApoE^{-/-} mice (Figure 2A-D). Increased plaque size did not correlate with an increase in weight gain or in cholesterol levels in T β 4^{-/-}; ApoE^{-/-} mice, compared with T β 4^{+/-}; ApoE^{-/-}, although mice of both genotypes weighed more than Myh11^{Cre}; *Lrp1*^{fl/fl}; ApoE^{-/-}, both at baseline and after high fat feeding (Online Figure II). Whilst our study initially examined male mice in HFD cohorts, the unanticipated observation of hindlimb paralysis, a possible indication of aortic thrombosis, aneurysm or rupture, prompted us to

investigate a cohort of regular chow-fed 8 month old female $T\beta 4^{-/-}$; $ApoE^{-/-}$ and age-matched $T\beta 4^{+/+}$; $ApoE^{-/-}$ mice. Even without a cholesterol-rich diet, aortas of $T\beta 4^{-/-}$; $ApoE^{-/-}$ mice were aneurysmal (>1.5 fold dilated), compared with $T\beta 4^{+/+}$; $ApoE^{-/-}$, and contained large atherosclerotic plaques (Figure 2E-G). In view of the increasingly recognised sexual dimorphism in vascular disease, both in patients and in experimental animals³⁴, we compared a further cohort of female mice, this time with HFD over an equivalent time course to that used in male cohorts, and determined a significant increase in aortic arch plaque size in $T\beta 4^{-/-}$; $ApoE^{-/-}$, compared with $T\beta 4^{+/+}$; $ApoE^{-/-}$ mice (Online Figure III). Interestingly, in female mice, as compared to male mice, increased plaque size did correlate with increased weight gain in $T\beta 4^{-/-}$; $ApoE^{-/-}$ mice, compared with $T\beta 4^{+/+}$; $ApoE^{-/-}$. Taken together, these studies suggest that atherogenesis is accelerated in $T\beta 4$ null mice, regardless of gender, and closely recapitulates the phenotype associated with loss of LRP1.

Accelerated plaque formation is not due to exacerbated inflammation from loss of $T\beta 4$

Acknowledging the prominent underlying role of inflammation in the initiation and progression of vascular disease, and the numerous anti-inflammatory roles ascribed to $T\beta 4$ ³⁵⁻³⁷, we characterised the inflammatory responses of $T\beta 4^{-/-}$; $ApoE^{-/-}$ and $T\beta 4^{+/+}$; $ApoE^{-/-}$ mice during atherosclerosis. Quantitative reverse transcription real-time PCR (qRT-PCR) indicated comparable expression of pro-inflammatory cytokines *Il1b* and *Tnfα* in descending aorta biopsies between genotypes at 3, 7, 9 and 12 weeks' HFD (Figure 3A). Similarly, levels of pro-inflammatory cytokines, Interferon (IFN) γ , Interleukin (IL)-6 and Tumor necrosis factor (TNF) α , in peripheral blood were not significantly different between genotypes (Figure 3B). This was borne out in the quantification of immune cells recruited to aortic lesions. Monocyte (CD45+CD11b+CD14+) content of the descending aorta was assessed by flow cytometry and found to be comparable between genotypes (Figure 3C). Recruited monocytes were further defined based on expression of the chemokine receptor CCR2, implicated in recruitment of monocyte-derived macrophages to the aorta and development of AAA³⁸. The number of recruited CD45+CD11b+CD14+CCR2+ macrophages was indistinguishable between $T\beta 4^{-/-}$; $ApoE^{-/-}$ and $T\beta 4^{+/+}$; $ApoE^{-/-}$ (Figure 3C). Finally, we assessed macrophage/foam cell content of aortic sinus plaques, based on CD68 immunofluorescence (IMF; Figure 3D). After quantification, plaque composition, in terms of necrotic core and area occupied by macrophages, was indistinguishable between $T\beta 4^{-/-}$; $ApoE^{-/-}$ and $T\beta 4^{+/+}$; $ApoE^{-/-}$ (Figure 3D). These data exclude a causative difference in inflammatory response in $T\beta 4$ mutants as being responsible for exacerbated disease progression.

Phenotypic modulation of VSMCs is accelerated in $T\beta 4$ -null mice

Since T β 4 has been implicated in VSMC differentiation during development and the transcriptomic analyses above support a correlative role for the peptide in preservation of contractile phenotype, we focused our investigation on VSMC phenotype and tracked their transition as they de-differentiate in increasing numbers over the course of HFD feeding. After 7 weeks, the medial layer VSMCs of T β 4^{-/-}; ApoE^{-/-} mice displayed a pronounced alteration in morphology, with loss of their characteristic, elongated shape and acquisition of a smaller, more rounded appearance (Figure 4A). This was associated with a shift in the ratio of synthetic over contractile markers; by IMF, a striking decrease in α SMA was accompanied by a concomitant increase in Caldesmon and Vimentin levels (Figure 4A). T β 4^{+/-}; ApoE^{-/-} VSMCs underwent a similar shift, only this occurred more gradually, becoming noticeable from 9 weeks' HFD, once plaques were already established (Figure 4A). By qRT-PCR, a significantly greater decrease in the ratios of contractile:synthetic genes (*Sm22 α* : *caldesmon* and *Myh11*: *vimentin*) was apparent in T β 4^{-/-}; ApoE^{-/-} mice, compared with T β 4^{+/-}; ApoE^{-/-} (Figure 4B). Moreover, western blotting demonstrated a decrease in expression of contractile marker Calponin1 and confirmed that the overall rise in Caldesmon levels results from a proportionally larger increase in the lower molecular weight isoforms that are associated with the synthetic phenotype^{6, 39} (Figure 4C). Consistent with dedifferentiation and acquisition of a synthetic phenotype, medial VSMCs were significantly more proliferative, as determined by increased EdU incorporation between weeks 5 and 7 of HFD feeding (Figure 4D); in contrast, cells within the plaque showed no difference in proliferation between genotypes at this stage (Figure 4E). Altogether, these data demonstrate that T β 4^{-/-} VSMCs undergo an accelerated de-differentiation during atherosclerosis, to more rapidly become 'synthetic' in phenotype, compared with T β 4^{+/-} VSMCs, and potentially compromise vascular stability.

Vascular integrity and plaque stability is compromised in T β 4-null mice

Vascular stability in the face of atherosclerotic disease is dependent upon the maintenance of viable, contractile VSMCs and the integrity of the elastin-rich matrix that they deposit. Specifically, VSMCs of the fibrous cap play an important role in ECM synthesis, to stabilize plaques and protect against rupture and thrombosis³. Phenotypic modulation of VSMCs frequently precedes senescence and apoptosis^{40, 41}, to further destabilise affected vessels. A striking degeneration of the elastin lamellae was apparent in T β 4^{-/-}; ApoE^{-/-} aortas, with more elastin breaks per section than in T β 4^{+/-}; ApoE^{-/-} aortas and a higher elastin damage score (Figure 5A). By these parameters, elastin degeneration in T β 4^{-/-}; ApoE^{-/-} aortas was comparable with, and in some cases more severe than, Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} aortas (Figure 5A). The serine protease high-temperature requirement factor A1(HTRA1), abundantly expressed in VSMCs⁴², was proposed to contribute towards the excessive

elastolysis observed in VSMC-specific *Lrp1* KO aortas, as it depends upon LRP1-mediated endocytosis for clearance⁴³. We found HTRA1 protein levels to be elevated in the medial and sub-intimal layers of $T\beta 4^{-/-}$; *ApoE*^{-/-} aortas, compared with those in $T\beta 4^{+/+}$; *ApoE*^{-/-} mice (Figure 5B), which may contribute towards the exacerbated elastin fragmentation and further supports the notion that endocytic clearance via LRP1 requires $T\beta 4$. Finally, Masson's Trichrome staining revealed extensive plaque fibrosis between 7-12 weeks (Figure 5C, shown at 12 weeks), and, while collagen content per section was greater in $T\beta 4^{-/-}$; *ApoE*^{-/-} and *Myh11*^{Cre}; *Lrp1*^{fl/fl}; *ApoE*^{-/-}, compared with $T\beta 4^{+/+}$; *ApoE*^{-/-}, it was consistently proportional to plaque size. Therefore, while mutant plaques were larger, % plaque collagen content was not disproportionately higher than control (Figure 5C). We measured fibrous cap thickness, relative to lesion thickness, after 12 weeks and, whilst this was comparable between genotypes, the caps of $T\beta 4^{-/-}$; *ApoE*^{-/-} plaques were composed of cells expressing predominantly synthetic markers, such as Caldesmon (Figure 5D). In comparison, control $T\beta 4^{+/+}$; *ApoE*^{-/-} cap cells retained higher levels of contractile markers, such as α SMA (Figure 5D). Of note, a significantly higher proportion of $T\beta 4^{-/-}$; *ApoE*^{-/-} medial VSMCs and cells that comprise the fibrous cap were apoptotic, as revealed by TUNEL staining, compared with $T\beta 4^{+/+}$; *ApoE*^{-/-} (Figure 5E). Thus, the preponderance of apoptotic and synthetic VSMCs, relative to the number of contractile VSMCs, suggests that, despite having thick fibrous caps, plaques in $T\beta 4^{-/-}$; *ApoE*^{-/-} mice may be more unstable than those in $T\beta 4^{+/+}$; *ApoE*^{-/-} mice. Taken together, the modulated VSMC phenotype and aggravated elastolysis are likely to destabilise the aortic wall and accelerate atherogenesis in $T\beta 4$ -LRP1 deficient mice; moreover, those plaques that form are predicted, based on lesion size as well as cap VSMC phenotype, to be more prone to rupture.

LRP1-controlled growth factor signaling is dysregulated in $T\beta 4$ -null mice

The protective, VSMC-autonomous function of LRP1 has been attributed to the endocytic control of PDGFR β signalling, as well as to the endocytic clearance of matricellular proteins that are responsible for ECM remodelling^{43, 44}. Our demonstration that $T\beta 4^{-/-}$ phenocopy VSMC-specific LRP1 KO, in their susceptibility to atherosclerotic plaque formation, aggravated elastolysis and compromised clearance of HTRA1, raises the possibility that defects in $T\beta 4$ mutants are, similarly, due to LRP1-PDGFR β pathway dysregulation. We therefore assessed readouts of the LRP1-PDGFR β pathway in medial layer VSMCs at early-intermediate disease stages, which coincide with initiation of injury-provoked phenotypic switching. Tyr1021 PDGFR β phosphorylation, which reports the extent of receptor autophosphorylation following ligand binding and LRP1-mediated endocytosis⁴⁵, was elevated 2.4-fold in VSMCs of $T\beta 4^{-/-}$; *ApoE*^{-/-} aortas, compared with $T\beta 4^{+/+}$; *ApoE*^{-/-} aortas, by

immunofluorescence (Figure 6A). Similarly, levels of Tyr 4507 phospho-LRP1, resulting from phosphorylation by PDGFR β ^{46,47}, were elevated 1.8-fold (Figure 6A). Receptor phosphorylation is coupled via adaptor protein binding and phosphatidylinositol 3-kinase (PI3K) activation to downstream effectors, including AKT and p42/p44 MAP kinase (ERK1/2)⁴⁸. By western blotting, phosphorylated (activated) AKT and p42/p44 MAP kinase were significantly higher in aortas of T β 4^{-Y}; ApoE^{-/-} aortas, compared with T β 4^{+Y}; ApoE^{-/-} aortas, by immunofluorescence (Figure 6B). These data indicate that accelerated phenotypic modulation of VSMCs and exacerbated atherosclerosis in T β 4^{-Y} mice is associated with dysregulated LRP1-PDGFR β pathway activity and point to a likely role for T β 4 in controlling receptor turnover, as previously elucidated in isolated VSMCs¹⁵, to influence the progression and outcome of atherosclerotic disease.

Discussion

Collectively, our study defines a key role for T β 4 to maintain medial VSMCs in a differentiated, contractile state to protect against atherosclerosis. T β 4 null mice on an atherogenic (ApoE^{-/-}) background develop large complex plaques, irrespective of gender, indicating that loss of T β 4 exacerbates disease progression. Assessment in both genders was important, due to the increasing reports of sexual dimorphism, both in patients and in experimental studies of cardiovascular disease³⁴. Accelerated disease progression was characterized by augmented VSMC phenotypic modulation and underpinned by dysregulated PDGFR β signaling and deleterious ECM remodelling, both of which may result from a failure of T β 4 to functionally regulate LRP1 trafficking. Mechanistically, T β 4 has been shown to bind the intracellular domain of LRP1, near NPxY domains that are necessary for signal transduction and endocytosis; accordingly, T β 4 controls the balance between recycling and lysosomal targeting of LRP1-PDGFR β complexes, to critically regulate VSMC sensitivity and responses to PDGF-BB¹⁵. Consistent with this, vascular defects in T β 4 null mice closely phenocopy those reported with VSMC-specific loss of LRP1^{13, 20, 33}, not only at baseline and in AAA¹⁵, but also, herein, in atherosclerotic disease. Thus, our findings further add support to the existence of a common regulatory mechanism through which T β 4 and LRP1 act in vascular homeostasis to maintain vessel stability and protect against disease.

The significance of VSMC phenotypic switching in atherosclerosis is still not fully resolved³. While abnormal proliferation and migration of VSMCs drives early lesion formation and, debatably, may contribute pro-inflammatory macrophage-like cells to the plaque^{23, 49, 50}, VSMC-derived 'fibromyocytes' are beneficial in stabilising more advanced plaques to prevent fibrous cap rupture. Thereafter, however, prolonged VSMC transformation perpetuates the

inflammatory environment and promotes pathogenic remodelling, causing intimal thickening, arterial stiffness and stenosis⁹. Understanding VSMC heterogeneity, and identifying the regulators of phenotypic modulation may enable the fine tuning of VSMC phenotypes that are beneficial for repair. Transcriptomic and proteomic analyses at single cell resolution make this an attainable goal within the next decade.

A limitation of this study is that global deletion does not allow us to distinguish cell type-specific roles for T β 4. While it was important to exclude inflammation as the primary reason for accelerated disease progression in T β 4^{-/-}; ApoE^{-/-} mice, given the array of anti-inflammatory roles ascribed to T β 4^{35, 37, 51} and LRP1⁵², a comprehensive immune cell profiling is required to categorically exclude roles beyond macrophage recruitment. Although correlative, the scRNA-seq analysis and validation in plaque sections strongly supports a cell-autonomous requirement for T β 4 in VSMCs for preservation of differentiated contractile phenotype. When taken together with the prior demonstration of baseline defects and AAA predisposition after VSMC-specific depletion of T β 4¹⁵, an endogenous role within VSMCs appears, overall, most likely, but still requires further investigation.

LRP1 is increasingly recognised for its central role in protection against cardiovascular disease, with mutations in the gene now implicated through genome-wide association studies as a causal factor in AAA¹⁷, carotid artery¹⁸ and coronary artery disease¹⁹. From these studies, it appeared logical that the genetic predisposition should result from defects, either in the removal of proatherogenic lipids via the liver or in exacerbated LDL uptake by macrophage and conversion to foam cells⁵³. However, animal studies were instrumental in enabling selective targeting in macrophages⁵⁴, endothelial cells⁵⁵, VSMCs⁵⁶, perivascular adipose tissue⁵⁷ and hepatocytes⁵⁸ to discriminate roles for LRP1 in the respective cell types. While LRP1 is instrumental in macrophages to maintain cholesterol efflux⁵⁹ and enable efferocytosis^{60, 61}, distinct, vasculoprotective functions were defined for LRP1 in VSMCs, predominantly in the control of growth factor signalling and ECM remodelling^{13, 20, 56}. That loss of T β 4, a molecular regulator of LRP1 endocytosis, recapitulates the phenotype of LRP1-depleted VSMCs emphasises the importance of controlled receptor trafficking in determining medial VSMC responses and progression of AAA and atherosclerosis.

Author contributions

SM, ANR and NS carried out most experiments and data analysis, with computational analysis of scRNA-Seq data by ANR and BP. NS established the hypotheses, supervised the study and wrote the manuscript. All authors edited and approved the manuscript.

Acknowledgements

The study was funded primarily by the British Heart Foundation Ian Fleming Senior Basic Science Research Fellowship (FS/13/4/30045), awarded to NS, and also by a studentship from the Oxford Medical Research Council Doctoral Training Partnership to SM.

References

1. Alexander Y, Osto E, Schmidt-Trucksass A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Back M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat ML and Evans PC. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. *Cardiovascular research*. 2021;117:29-42.
2. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD and Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol*. 1995;15:1512-31.
3. Bennett MR, Sinha S and Owens GK. Vascular Smooth Muscle Cells in Atherosclerosis. *Circulation research*. 2016;118:692-702.
4. Herrington W, Lacey B, Sherliker P, Armitage J and Lewington S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. *Circulation research*. 2016;118:535-46.
5. Bochaton-Piallat ML and Back M. Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification. *Cardiovascular research*. 2018;114:477-480.
6. Rensen SS, Doevendans PA and van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. *Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation*. 2007;15:100-8.

7. Basatemur GL, Jorgensen HF, Clarke MCH, Bennett MR and Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol.* 2019;16:727-744.
8. Hu D, Yin C, Luo S, Habenicht AJR and Mohanta SK. Vascular Smooth Muscle Cells Contribute to Atherosclerosis Immunity. *Front Immunol.* 2019;10:1101.
9. Sandison ME, Dempster J and McCarron JG. The transition of smooth muscle cells from a contractile to a migratory, phagocytic phenotype: direct demonstration of phenotypic modulation. *J Physiol.* 2016;594:6189-6209.
10. Wu J, Zhang Y, Yang P, Enkhjargal B, Manaenko A, Tang J, Pearce WJ, Hartman R, Obenaus A, Chen G and Zhang JH. Recombinant Osteopontin Stabilizes Smooth Muscle Cell Phenotype via Integrin Receptor/Integrin-Linked Kinase/Rac-1 Pathway After Subarachnoid Hemorrhage in Rats. *Stroke.* 2016;47:1319-27.
11. Armulik A, Abramsson A and Betsholtz C. Endothelial/pericyte interactions. *Circulation research.* 2005;97:512-23.
12. Evanko SP, Raines EW, Ross R, Gold LI and Wight TN. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. *Am J Pathol.* 1998;152:533-46.
13. Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, Anderson RG and Herz J. LRP1 functions as an atheroprotective integrator of TGFbeta and PDGF signals in the vascular wall: implications for Marfan syndrome. *PLoSOne.* 2007;2:e448.
14. Muratoglu SC, Mikhailenko I, Newton C, Migliorini M and Strickland DK. Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activation of the MAPK pathway. *JBiolChem.* 2010;285:14308-14317.
15. Munshaw S, Bruche S, Redpath AN, Jones A, Patel J, Dube KN, Lee R, Hester SS, Davies R, Neal G, Handa A, Sattler M, Fischer R, Channon KM and Smart N. Thymosin beta4 protects against aortic aneurysm via endocytic regulation of growth factor signaling. *J Clin Invest.* 2021;131.
16. Rossdeutsch A, Smart N, Dube KN, Turner M and Riley PR. Essential role for thymosin beta4 in regulating vascular smooth muscle cell development and vessel wall stability. *CircRes.* 2012;111:e89-102.
17. Brown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, Gretarsdottir S, Badger SA, Bradley DT, Burnand K, Child AH, Clough RE, Cockerill G, Hafez H, Scott DJ,

Futers S, Johnson A, Sohrabi S, Smith A, Thompson MM, van Bockxmeer FM, Waltham M, Matthiasson SE, Thorleifsson G, Thorsteinsdottir U, Blankensteijn JD, Teijink JA, Wijmenga C, de Graaf J, Kiemeny LA, Assimes TL, McPherson R, Folkersen L, Franco-Cereceda A, Palmen J, Smith AJ, Sylviu N, Wild JB, Refstrup M, Edkins S, Gwilliam R, Hunt SE, Potter S, Lindholt JS, Frikke-Schmidt R, Tybjaerg-Hansen A, Hughes AE, Golledge J, Norman PE, van Rij A, Powell JT, Eriksson P, Stefansson K, Thompson JR, Humphries SE, Sayers RD, Deloukas P and Samani NJ. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. *American journal of human genetics*. 2011;89:619-27.

18. Giusti B, Galora S, Saracini C, Pratesi G, Gensini GF, Pulli R, Pratesi C and Abbate R. Role of rs1466535 low density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism in carotid artery disease. *Atherosclerosis*. 2014;237:135-7.

19. Webb TR, Erdmann J, Stirrups KE, Stitzel NO, Masca NG, Jansen H, Kanoni S, Nelson CP, Ferrario PG, König IR, Eicher JD, Johnson AD, Hamby SE, Betsholtz C, Ruusalepp A, Franzen O, Schadt EE, Björkegren JL, Weeke PE, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kruppa J, Mahajan A, Scott RA, Willenborg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer C, El-Mokhtari NE, Franke A, Heilmann S, Hengstenberg C, Hoffmann P, Holmen OL, Hveem K, Jansson JH, Jöckel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Virtamo J, Nikpay M, Olivieri O, Provost S, AlQarawi A, Robertson NR, Akinkansoy KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Müller-Nurasyid M, Strauch K, Varga TV, Waldenberger M, Zeng L, Chowdhury R, Salomaa V, Ford I, Jukema JW, Amouyel P, Kontto J, Nordestgaard BG, Ferrières J, Saleheen D, Sattar N, Surendran P, Wagner A, Young R, Howson JM, Butterworth AS, Danesh J, Ardisino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, Kastrati A, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CN, Peters A, Rader DJ, Reilly MP, Loos RJ, Reiner AP, Roden DM, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Samani NJ, Schunkert H, Deloukas P and Kathiresan S. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2017;69:823-836.

20. Boucher P, Gotthardt M, Li WP, Anderson RG and Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. *Science*. 2003;300:329-332.

21. Wirth A, Benyo Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horvath B, Maser-Gluth C, Greiner E, Lemmer B, Schutz G, Gutkind JS and Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *NatMed*. 2008;14:64-68.
22. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM and Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*. 1992;89:4471-5.
23. Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, Kundu R, Nagao M, Collier J, Koyano TK, Fong R, Woo YJ, Liu B, Montgomery SB, Wu JC, Zhu K, Chang R, Alamprese M, Tallquist MD, Kim JB and Quertermous T. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. *Nature medicine*. 2019;25:1280-1289.
24. Butler A, Hoffman P, Smibert P, Papalexi E and Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*. 2018;36:411-420.
25. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, Hao Y, Stoeckius M, Smibert P and Satija R. Comprehensive Integration of Single-Cell Data. *Cell*. 2019;177:1888-1902.e21.
26. Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, Ginhoux F and Newell EW. Dimensionality reduction for visualizing single-cell data using UMAP. *Nat Biotechnol*. 2018.
27. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh PR and Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods*. 2019;16:1289-1296.
28. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, Calif)*. 2001;25:402-8.
29. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ and Owens GK. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. *Nature medicine*. 2015;21:628-37.
30. Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, Cassella CP, Moore KJ, Ramsey SA, Miano JM and Fisher EA. Cholesterol loading reprograms the microRNA-

143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. *Arterioscler Thromb Vasc Biol.* 2015;35:535-46.

31. Smart N, Dube KN and Riley PR. Identification of Thymosin beta4 as an effector of Hand1-mediated vascular development. *NatCommun.* 2010;1:46.

32. Smart N, Risebro CA, Melville AAD, Moses KA, Schwartz RJ, Chien KR and Riley PR. Thymosin b4 induces adult epicardial progenitor mobilization and neovascularization. *Nature.* 2007;445:177-182.

33. Davis FM, Rateri DL, Balakrishnan A, Howatt DA, Strickland DK, Muratoglu SC, Haggerty CM, Fornwalt BK, Cassis LA and Daugherty A. Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms. *Arterioscler Thromb Vasc Biol.* 2015;35:155-62.

34. Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS and Smith JD. Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. *Arterioscler Thromb Vasc Biol.* 2018;38:292-303.

35. Evans MA, Smart N, Dube KN, Bollini S, Clark JE, Evans HG, Taams LS, Richardson R, Levesque M, Martin P, Mills K, Riegler J, Price AN, Lythgoe MF and Riley PR. Thymosin beta4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. *Nature communications.* 2013;4:2081.

36. Gupta S, Kumar S, Sopko N, Qin Y, Wei C and Kim IK. Thymosin beta4 and cardiac protection: implication in inflammation and fibrosis. *AnnNYAcadSci.* 2012;1269:84-91.

37. Sosne G, Chan CC, Thai K, Kennedy M, Szliter EA, Hazlett LD and Kleinman HK. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. *ExpEye Res.* 2001;72:605-608.

38. Patel J, McNeill E, Douglas G, Hale AB, de Bono J, Lee R, Iqbal AJ, Regan-Komito D, Stylianou E, Greaves DR and Channon KM. RGS1 regulates myeloid cell accumulation in atherosclerosis and aortic aneurysm rupture through altered chemokine signalling. *Nature communications.* 2015;6:6614.

39. Ueki N, Sobue K, Kanda K, Hada T and Higashino K. Expression of high and low molecular weight caldesmons during phenotypic modulation of smooth muscle cells. *Proceedings of the National Academy of Sciences of the United States of America.* 1987;84:9049-53.

40. Bennett MR and Boyle JJ. Apoptosis of vascular smooth muscle cells in atherosclerosis. *Atherosclerosis*. 1998;138:3-9.
41. Garrido AM and Bennett M. Assessment and consequences of cell senescence in atherosclerosis. *Curr Opin Lipidol*. 2016;27:431-8.
42. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG and Baldi A. Distribution of the serine protease HtrA1 in normal human tissues. *J Histochem Cytochem*. 2003;51:1279-84.
43. Muratoglu SC, Belgrave S, Hampton B, Migliorini M, Coksaygan T, Chen L, Mikhailenko I and Strickland DK. LRP1 protects the vasculature by regulating levels of connective tissue growth factor and HtrA1. *Arterioscler Thromb Vasc Biol*. 2013;33:2137-46.
44. Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK, Troeberg L and Nagase H. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. *The Journal of biological chemistry*. 2014;289:6462-6474.
45. Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschild C and Strickland DK. Platelet-derived Growth Factor Receptor- β (PDGFR- β) Activation Promotes Its Association with the Low Density Lipoprotein Receptor-related Protein (LRP): EVIDENCE FOR CO-RECEPTOR FUNCTION. *Journal of Biological Chemistry*. 2005;280:27872-27878.
46. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG and Herz J. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae. *JBiolChem*. 2002;277:15507-15513.
47. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA and Strickland DK. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. *JBiolChem*. 2002;277:15499-15506.
48. Andrae J, Gallini R and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. *Genes and Development*. 2008;22:1276-1312.
49. Chen PY, Qin L, Li G, Malagon-Lopez J, Wang Z, Bergaya S, Gujja S, Caulk AW, Murtada SI, Zhang X, Zhuang ZW, Rao DA, Wang G, Tobiasova Z, Jiang B, Montgomery RR, Sun L, Sun H, Fisher EA, Gulcher JR, Fernandez-Hernando C, Humphrey JD, Tellides G, Chittenden TW and Simons M. Smooth Muscle Cell Reprogramming in Aortic Aneurysms. *Cell Stem Cell*. 2020;26:542-557.e11.

50. Allahverdian S, Chaabane C, Boukais K, Francis GA and Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. *Cardiovascular research*. 2018;114:540-550.
51. Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ and Stevenson RD. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. *Nature medicine*. 1999;5:1424-7.
52. May P, Bock HH and Nofer JR. Low density receptor-related protein 1 (LRP1) promotes anti-inflammatory phenotype in murine macrophages. *Cell Tissue Res*. 2013;354:887-9.
53. Chen J, Su Y, Pi S, Hu B and Mao L. The Dual Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Atherosclerosis. *Frontiers in cardiovascular medicine*. 2021;8:682389.
54. Au DT, Migliorini M, Strickland DK and Muratoglu SC. Macrophage LRP1 Promotes Diet-Induced Hepatic Inflammation and Metabolic Dysfunction by Modulating Wnt Signaling. *Mediators Inflamm*. 2018;2018:7902841.
55. Mao H, Lockyer P, Li L, Ballantyne CM, Patterson C, Xie L and Pi X. Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARgamma. *Nature communications*. 2017;8:14960.
56. Muratoglu SC, Belgrave S, Hampton B, Migliorini M, Coksaygan T, Chen L, Mikhailenko I and Strickland DK. LRP1 Protects the Vasculature by Regulating Levels of Connective Tissue Growth Factor and HtrA1. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2013;33:2137-2146.
57. Konanah ES, Kuhel DG, Basford JE, Weintraub NL and Hui DY. Deficiency of LRP1 in Mature Adipocytes Promotes Diet-Induced Inflammation and Atherosclerosis-Brief Report. *Arterioscler Thromb Vasc Biol*. 2017;37:1046-1049.
58. Ding Y, Xian X, Holland WL, Tsai S and Herz J. Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis. *EBioMedicine*. 2016;7:135-45.
59. Xian X, Ding Y, Dieckmann M, Zhou L, Plattner F, Liu M, Parks JS, Hammer RE, Boucher P, Tsai S and Herz J. LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis. *Elife*. 2017;6.
60. Subramanian M, Hayes CD, Thome JJ, Thorp E, Matsushima GK, Herz J, Farber DL, Liu K, Lakshmana M and Tabas I. An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. *J Clin Invest*. 2014;124:1296-308.

61. Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF and Fazio S. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. *Arterioscler Thromb Vasc Biol.* 2010;30:787-95.

Figure Legends

Figure 1. Contractile VSMC Phenotype in atherosclerosis is correlated with expression of *Tmsb4x*. Uniform Manifold Approximation and Projection (UMAP) plots demonstrating transcriptomically distinct contractile (ContSMC1-3) and modulated (ModSMC) VSMC subpopulations of ApoE^{-/-} mice at baseline and after 8- and 16- weeks of high fat diet (HFD; **A**). UMAP showing changes in the expression of *Tmsb4x* across the VSMC subpopulations over the time course of atherosclerosis (**B**). Each dot is an individual cell and gene expression levels are indicated by the colour spectrum, with green representing high, orange medium and red-blue low *Tmsb4x* expression. n=3 for baseline, 8- and 16 weeks. Data re-analysed from ²³. *Tmsb4x* expression in the ModSMC cluster positively correlated with contractile marker expression, as shown for *Tagln*, and negatively correlated with synthetic markers, exemplified by *Spp1* (**C**). Pearson correlation coefficients are indicated above each plot. Validation by immunofluorescence in aortic sinus sections from ApoE^{-/-} male mice (**D**); T β 4 and α -smooth muscle actin (α -SMA) abundantly co-expressed in medial layer VSMCs at 3 weeks' HFD but expression of both declined by 7 weeks' HFD. Across both time points, Coloc2 quantified Pearson correlation coefficients ranged 0.64-0.75. Lumican was up-regulated with disease progression in medial (yellow arrowheads) and cap VSMCs (white arrowheads), which were largely devoid of T β 4 and α -SMA. Scale bar in **D**: 50 μ m.

Figure 2. T β 4-null mice develop larger atherosclerotic lesions. Oil red O staining of aortic sinus plaques from T β 4^{+/-}; ApoE^{-/-} (n=5), T β 4^{-/-}; ApoE^{-/-} (n=9) and Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} (n=5) mice. (**A**), with quantification of total plaque area in **C**. Plaques in the descending aorta from T β 4^{+/-}; ApoE^{-/-} (n=6), T β 4^{-/-}; ApoE^{-/-} (n=7) and Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} (n=7) mice, assessed by hematoxylin and eosin (H&E) staining, with quantification of total plaque area in **D**. Plaques were measure in 22-week old mice, after 12 weeks of high fat diet. Even without high fat diet, 8 month old females showed aortic dilatation (**E-F**) and larger plaque formation (**E-G**; n = 5). Data are presented as mean $\pm$ SD, with each data point representing an individual animal. Significance was calculated using one-way ANOVA with Tukey's multiple comparison tests (**C**, **D**) or Mann Witney non-parametric test with Holm-Sidak correction for multiple comparisons (**B**, **D**). n.s. = not significant; *p $\leq$ 0.05; **p $\leq$ 0.01. Scale bars: **A**: 500 μ m; **B**: 200 μ m; **E**: 500 μ m (magnified panels, right: 150 μ m).

Figure 3. Accelerated atherosclerosis is not due to exacerbated inflammation in T β 4-null mice. qRT-PCR of pro-inflammatory cytokines, *Il1 β* and *Tnfa*, from descending aortas of

T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice (n=5 at 3 and 9 weeks', n=6 at 7 weeks' and n=8 at 12 weeks' high fat diet). Serum from T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice were assayed by multiplexed automated ELISA for IFN γ , IL-6 and TNF α levels after 3 weeks' high fat diet (n = 5; **B**). Flow cytometry to quantify macrophages (M Φ) recruited to aortas of T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice after 3 weeks of high fat diet (gating strategy shown in **C**, with the percentage of CCR2⁺ macrophages out of total live cells shown. Quantification of total cells, CD11b⁺CD14⁺ monocytes, and CCR2⁺ recruited macrophages n = 4 T β 4^{+/-}; ApoE^{-/-} and n = 5 T β 4^{-/-}; ApoE^{-/-} mice. Immunofluorescence of CD68⁺ macrophage/foam cells in aortic sinus plaques (**D**) and quantification of plaque composition, in terms of % area occupied by macrophages and % area necrotic core (n = 12). Data are presented as mean $\pm$ SD, with each data point representing an individual animal. Significance was calculated using one-way ANOVA with Tukey's multiple comparison tests (**A**), Mann Witney non-parametric test (**B**, **D**), ANOVA with Bonferroni correction for multiple comparisons (**C**). n.s. = not significant. Scale bar in **D**: 250 μ m.

Figure 4. Phenotypic modulation of VSMCs is accelerated in T β 4-null mice. Contractile-synthetic phenotype in T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice tracked over the course of lesion formation by immunofluorescence (7-12 weeks' high fat diet, **A**). Boxed region in 9 week panel magnified in inset. Phenotype assessed quantitatively by qRT-PCR in **B** (9 weeks' high fat diet; n = 6). Western blot showing expression of contractile proteins (high molecular weight Caldesmon, Calponin1) and synthetic markers (low molecular weight Caldesmon) in aortic lysates from T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice (**C**; n = 6), with quantification for Calponin1, total Caldesmon and low : high ratio of Caldesmon. VSMC (**D**) and plaque cell (**E**) proliferation assessed by EdU incorporation (twice weekly pulses between 5-7 weeks and harvest at 7 weeks' high fat diet). Data are presented as mean $\pm$ SD, with each data point representing an individual animal. Significance was calculated using Mann Witney non-parametric test. n.s. = not significant; *p $\leq$ 0.05; **p $\leq$ 0.01; ***: p $\leq$ 0.001. Scale bars: **A**: 50 μ m (7 and 12 weeks); 100 μ m (9 weeks); **D**: 50 μ m; **E**: 250 μ m. med: medial layer.

Figure 5. Vascular integrity and plaque stability is compromised in T β 4-null mice. Verhoeff-van Gieson staining of abdominal aorta from T β 4^{+/-}; ApoE^{-/-} (n=11), T β 4^{-/-}; ApoE^{-/-} (n=13) and Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} (n=11) mice after 12 weeks' high fat diet, to visualize elastin integrity underlying the plaque (**A**), with quantification of elastin grade (1=normal; 2=occasional breaks; 3= frequent breaks, multiple lamellae; 4=severe breakdown) and number of breaks per section. Assessment of HTRA1 accumulation in T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} aortic sections (n=5) after 9 weeks' high fat diet (**B**). Fibrosis assessed by Masson's

Trichrome stain after 12 weeks' high fat diet, representative of n=11 T β 4^{+/-}; ApoE^{-/-}, n = 13 T β 4^{-/-}; ApoE^{-/-} and n=11 Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} (**C**). Fibrous cap thickness quantified, relative to lesion thickness (**D**). Assessment of apoptotic medial VSMCs and cap cells (TUNEL staining) after 7 and 9 weeks' high fat diet (**E**). Data are presented as mean $\pm$ SD, with each data point an average of 6 sections for each animal. Significance was calculated using one-way ANOVA with Tukey's multiple comparison tests (**A**) or Mann Witney non-parametric test (**B**, **D-E**). n.s. = not significant; *p $\leq$ 0.05; **p $\leq$ 0.01; ***: p $\leq$ 0.001; ****p $\leq$ 0.0001. med: medial layer; FCT: fibrous cap thickness; LT: lesion thickness. Scale bars: **A**: 200 μ m (upper); 100 μ m (lower); **B**: 50 μ m (upper) 10 μ m (lower); **C**: 100 μ m; **D**: 20 μ m; **E**: 50 μ m.

Figure 6. LRP1-controlled growth factor signaling is dysregulated in T β 4-null mice. Phospho-LRP1 (Tyr 4507) and Phospho-PDGFR β (Tyr1021) levels in medial VSMCs of T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} (n=4) after 3 weeks' high fat diet (**A**). Western blotting of downstream effectors, phosphorylated p42/p44 MAPK and AKT, expressed relative to total p42/p44 MAPK and AKT from n=6 T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} aortas after 7 weeks' high fat diet (n = 6; **B**). Data are presented as mean $\pm$ SD, with each data point representing an individual animal. Significance was calculated using a Mann Witney non-parametric test. * P $\leq$ 0.05; ** P $\leq$ 0.01. int: intima; med: media; adv; adventitia. Scale bars: **A**: 50 μ m.

Online Figure I. scRNA-seq of VSMCs in atherosclerosis.

A: Computational analysis of scRNA-seq of lineage traced aortic VSMCs from ApoE^{-/-} mice (derived from²³) identified 5 VSMC subpopulations, as shown in Figure 1. Heatmap illustrating the top 5 marker genes and their expression levels to characterise each cluster. **B:** Stacked bar plot depicting the proportions of each VSMC subpopulation at each time point, to illustrate VSMC modulation in atherosclerosis. **C:** Violin plots to demonstrate changes in *Tmsb4x* and *Lumican* expression across the five VSMC subpopulations over the disease time course.

Online Figure II. T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} do not show differences in weight gain or cholesterol levels after western diet. Comparison of weight gain (**A**) and plasma cholesterol levels (**B**) in T β 4^{+/-}; ApoE^{-/-} and T β 4^{-/-}; ApoE^{-/-} mice over the time course of the high fat diet feeding regime, compared with Myh11^{Cre}; Lrp1^{fl/fl}; ApoE^{-/-} mice. Data are presented as mean $\pm$ SD, with n=9-11 in **A**. Each data point in **B** represents an individual animal. Significance was calculated using two-way ANOVA with Bonferroni correction for multiple comparisons (**A**) and one-Way ANOVA with Tukey's multiple comparison tests (**B**). n.s. = not significant; ***: p $\leq$ 0.001

Online Figure III. Increased predisposition to atherosclerotic plaque formation was also observed in female $T\beta 4^{-/-}$; $ApoE^{-/-}$ mice. *En face* aorta preparations and oil red O staining to visualize plaques in female mice fed Western diet for 12 weeks (**A**). Quantification of plaque coverage in the aortic arch, thoracic aorta (TA), abdominal aorta (AA) and total aorta (**B**). Weight gain was significantly increased in female $T\beta 4^{-/-}$; $ApoE^{-/-}$, compared with $T\beta 4^{-/-}$; $ApoE^{-/-}$ mice from 4-12 weeks' high fat diet feeding (**C**). Data are presented as mean $\pm$ SD, with each data point representing an individual animal (**B**) and n=8 (**C**). Significance was calculated using one-way ANOVA with Tukey's multiple comparison tests (**B**) and two-way ANOVA with Dunnett's post hoc tests (**C**). n.s.= not significant; * $p \leq 0.05$; ** $p \leq 0.01$; ***: $p \leq 0.001$.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6